HIV Vaccine Development: Current Status, Challenges, and Hope

Current Status

No licensed HIV vaccine exists. Despite 40+ years of research, no candidate has demonstrated sufficient efficacy for licensure.

Why Is It So Hard?

  • Extreme genetic diversity: HIV mutates rapidly; multiple clades/subtypes globally.
  • Immune evasion: Glycan shield on envelope (gp120); downregulation of MHC; latency in reservoirs.
  • No natural immunity model: No one clears HIV spontaneously → no correlate of protection to mimic.
  • Target vulnerability: CD4+ T cells (the very cells needed for immune response) are infected.
  • Mucosal transmission: Vaccine must induce mucosal immunity (IgA, tissue-resident T cells).

Major Clinical Trials

TrialStrategyResult
RV144 (Thai)ALVAC (canarypox) prime + AIDSVAX gp120 boost31% efficacy at 18 mo; waned to 0% by 3.5 yr. First signal of efficacy.
HVTN 702 (Uhambo)RV144 adapted for clade C (S. Africa)Stopped 2020: no efficacy (129 vs 123 infections).
HVTN 705/706 (Imbokodo/Mosaico)Mosaic immunogen (Ad26 prime + gp140 boost)Imbokodo (women): stopped 2021 (no efficacy). Mosaico (MSM/trans): stopped 2023 (no efficacy).
PrEPVaccDNA + protein + PrEP (ongoing)Results pending.

Promising Directions

  • Broadly neutralizing antibodies (bNAbs): Passive infusion (VRC01, 3BNC117) shows prevention; engineering for longevity/breadth.
  • mRNA platforms: Moderna, IAVI, Scripps testing germline-targeting, mosaic immunogens.
  • T-cell vaccines: Target conserved internal proteins (Gag, Pol) – HTI, conserved mosaic.
  • Combination approaches: bNAbs + vaccine; therapeutic + preventive.

Prevention Today

While vaccine research continues, PrEP (oral, long-acting injectable cabotegravir), PEP, TasP (U=U), condoms, syringe services are highly effective tools. Ending HIV requires both biomedical and structural interventions.

HIV & AIDS - Related Articles